Eyenovia engages Chardan for strategic alternatives evaluation while developing its Optejet ophthalmic dispensing platform.
Quiver AI Summary
Eyenovia, Inc., an ophthalmic technology company, has announced it is consulting with Chardan as its financial advisor to explore various strategic alternatives, including potential business combinations, asset sales, or a reverse merger, while managing expenses. The company continues to develop its Optejet device, which is intended for use as a consumer product and a drug-device combination, and it may be available by the end of the year without requiring clinical trials. Eyenovia has not yet set a timeline for the strategic review and has not reached any decisions regarding specific alternatives. They caution that any evaluation may not lead to successful transactions or improvements in shareholder value.
Potential Positives
- Eyenovia is actively exploring strategic alternatives with the help of Chardan, which could lead to significant growth or change opportunities for the company.
- The company continues to advance its Optejet device, indicating progress in their product development and potential market readiness.
- The possibility of the Optejet device being available as a user-filled product could expedite its market entry by bypassing the traditional clinical trial route, enhancing revenue potential.
Potential Negatives
- The press release indicates that Eyenovia is exploring a range of strategic alternatives, implying potential financial difficulties or uncertainty about the company's future direction.
- The statement that there can be no assurance the evaluation will lead to favorable transactions could raise concerns among investors regarding the company's viability and strategic planning.
- The lack of a definitive timeline for concluding the strategic review may create uncertainty for stakeholders about the company's plans and operational stability.
FAQ
What strategic alternatives is Eyenovia considering?
Eyenovia is exploring various strategic alternatives, including business combinations, asset sales, or a reverse merger.
What is the Optejet platform?
The Optejet is a topical ophthalmic medication dispensing platform designed for chronic front-of-the-eye diseases, enhancing safety and treatment compliance.
Who is Eyenovia's financial advisor?
Eyenovia has engaged Chardan as its financial advisor to assist in evaluating strategic alternatives.
When could the user-filled Optejet product be available?
The user-filled Optejet product could potentially be commercially available by the end of this year.
Will Eyenovia make further comments during the review process?
The company does not intend to comment further until the review process is concluded or other disclosures are appropriate.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYEN Insider Trading Activity
$EYEN insiders have traded $EYEN stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EYEN stock by insiders over the last 6 months:
- MICHAEL M ROWE (Chief Executive Officer) has traded it 2 times. They made 2 purchases, buying 77,071 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EYEN Hedge Fund Activity
We have seen 14 institutional investors add shares of $EYEN stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 2,473,741 shares (+40.8%) to their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 362,183 shares (-100.0%) from their portfolio in Q3 2024
- JANE STREET GROUP, LLC removed 190,285 shares (-83.3%) from their portfolio in Q3 2024
- NORTHERN TRUST CORP removed 189,462 shares (-75.5%) from their portfolio in Q3 2024
- DIAMETRIC CAPITAL, LP added 157,966 shares (+inf%) to their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 149,471 shares (+36.6%) to their portfolio in Q3 2024
- Y-INTERCEPT (HONG KONG) LTD removed 94,615 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger, asset sale, or a combination of alternatives, while also carefully managing its expenses.
Along with the evaluation of strategic alternatives, Eyenovia continues to progress development of its advanced Optejet device and is exploring options for use as both a consumer “user-filled” product and a proprietary drug-device combination. The user-filled product would advance through a device regulatory pathway without the need for clinical trials and could be commercially available by the end of this year.
The Company has not set a timetable for the conclusion of its review and has not made any decisions related to specific strategic alternatives at this time. The Company does not intend to comment further unless or until its Board of Directors has approved a definitive course of action, the review process has concluded, or it is determined that other disclosure is appropriate.
There can be no assurance that this evaluation will result in any definitive documentation to consummate one or more transactions, or other strategic changes or outcomes, or that the terms of any such transactions, changes, or outcomes will be favorable. Even if the Company enters into a definitive agreement, the Company may not be successful in completing a transaction, strategic change or outcome, or, if it completes such a transaction, strategic change or outcome, it may not ultimately enhance value or deliver expected benefits.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic technology company developing its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. For more information, please visit Eyenovia.com.
Forward Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including those relating to the estimated market opportunities for our platform technology, the regulatory pathway and timing for availability of our products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.
In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the regulatory pathway that would apply to our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Eyenovia Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
